NCT05511064

CEFID-II (CEra Flow Improves DVT-II)

A Multiple Center, Clinical Trial to Evaluate the Efficacy and Safety of Blood Circulation Improvement Using an Investigational Device (Model Name CGM MB-1701) for the Risk Group of Deep Vein Thrombosis (DVT)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Ceragem Clinical Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

For Deep Vein Thrombosis (DVT) risk groups, the effect and safety of blood circulation improvement before and after application are evaluated using an investigational device (model name CGM MB-1701).

Detailed description

The investigator applies the test device to the appropriate subjects for a total of 10 days (+1 days) at the institution and nursing hospital, and upon discharge for long-term follow-up investigation, the investigational device is applied at subjects' home according to the subject's consent for about 3 months.

Conditions

• Blood Circulation Disorder
• Deep Vein Thrombosis

Interventions

Type	Name	Description
DEVICE	Blood circulation device	Blood circulation device of CGM MB-1701

Timeline

• Start date: 2022-12-22
• Primary completion: 2024-10-28
• Completion: 2024-10-28
• First posted: 2022-08-22
• Last updated: 2026-02-05

Locations

3 sites across 1 country: South Korea